Transforming growth factor-β1 expression in dilated cardiomyopathy
暂无分享,去创建一个
J. Sanderson | K. Lai | L. Chow | S. Wei | I. Shum
[1] G. Cuda,et al. Changes in myocardial cytoskeletal intermediate filaments and myocyte contractile dysfunction in dilated cardiomyopathy: an in vivo study in humans , 2000, Heart.
[2] T. Kieser,et al. Tetrahydrobiopterin improves endothelial function in human saphenous veins. , 2000, The Journal of thoracic and cardiovascular surgery.
[3] K. Yokota,et al. Cholesterol modulates vascular reactivity to endothelin-1 by stimulating a pro-inflammatory pathway. , 2000, Biochemical and biophysical research communications.
[4] H. Lodish,et al. Role of transforming growth factor beta in human disease. , 2000, The New England journal of medicine.
[5] W. Hsueh,et al. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. , 2000, Circulation.
[6] C. Wanner,et al. CyA and OxLDL cause endothelial dysfunction in isolated arteries through endothelin-mediated stimulation of O(2)(-) formation. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[7] H P Schultheiss,et al. Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. , 1999, Circulation.
[8] T. Lüscher,et al. Tetrahydrobiopterin and endothelial function. , 1998, European heart journal.
[9] R. Mangiafico,et al. Raised plasma endothelin-1 concentrations in patients with primary hypercholesterolemia without evidence of atherosclerosis. , 1996, International angiology : a journal of the International Union of Angiology.
[10] B. Strauer,et al. Immunohistological characterization of infiltrating lymphocytes in biopsies of patients with clinically suspected dilated cardiomyopathy. , 1994, European heart journal.